Bill Text: GA SB248 | 2009-2010 | Regular Session | Introduced
Bill Title: Ga. Prescription Monitoring Program Act; monitoring of prescribing and dispensing controlled substances by the Ga State Board of Pharmacy
Spectrum: Partisan Bill (Republican 3-0)
Status: (Introduced - Dead) 2009-03-05 - Senate Read and Referred [SB248 Detail]
Download: Georgia-2009-SB248-Introduced.html
09 LC 33
3070
Senate
Bill 248
By:
Senators Shafer of the 48th, Chance of the 16th and Douglas of the 17th
A
BILL TO BE ENTITLED
AN ACT
AN ACT
To
amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating
to controlled substances, so as to enact the "Georgia Prescription Monitoring
Program Act"; to provide for legislative intent; to provide for definitions; to
provide for the establishment of a program for the monitoring of prescribing and
dispensing Schedule II, III, IV, or V controlled substances by the Georgia State
Board of Pharmacy; to require dispensers to submit certain information regarding
the dispensing of certain drugs; to provide for the confidentiality of submitted
information except under certain circumstances; to authorize the Georgia Drugs
and Narcotics Agency to contract for services relating to the program; to
provide for notice and information to prescribers and dispensers; to provide for
the establishment of a Prescription Monitoring Program Advisory Committee; to
provide for its membership, duties, and organization; to provide for the
establishment of rules and regulations; to provide for penalties; to provide for
limited liability; to provide for related matters; to provide for an effective
date; to repeal conflicting laws; and for other purposes.
BE
IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:
SECTION
1.
Chapter
13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled
substances, is amended by adding a new article to read as follows:
"ARTICLE
6
16-13-120.
This
article shall be known and may be cited as the 'Georgia Prescription Monitoring
Program Act.'
16-13-121.
This
article is intended to improve the state's ability to identify and stop
diversion of prescription drugs in an efficient and cost-effective manner that
will not impede the appropriate medical utilization of licit controlled
substances or other licit drugs with potential for abuse while minimizing impact
on pharmacy operations.
16-13-122.
As
used in this article, the term:
(1)
'Agency' means the Georgia Drugs and Narcotics Agency.
(2)
'Board' means the Georgia State Board of Pharmacy.
(3)
'Controlled substance' has the same meaning given such term in paragraph (4) of
Code Section 16-13-21.
(4)
'Dispenser' means a person that delivers a Schedule II, III, IV, or V controlled
substance to the ultimate user but shall not include:
(A)
A licensed pharmacy of a hospital that dispenses such substances for the purpose
of inpatient or outpatient hospital care, a licensed pharmacy of a hospital or
retail pharmacy of a hospital that dispenses prescriptions for controlled
substances at the time of dismissal or discharge from such a facility, or a
licensed pharmacy of a hospital or retail pharmacy of a hospital that dispenses
such substances for long-term care patients or inpatient hospice
facilities;
(B)
An institutional pharmacy that serves only a health care facility, including,
but not limited to, a nursing home, an intermediate care home, a personal care
home, or a hospice program, which provides inpatient care and which pharmacy
dispenses such substances to be administered and used by a patient on the
premises of the facility;
(C)
A practitioner or other authorized person who administers such a substance;
or
(D)
A pharmacy operated by, on behalf of, or under contract with the Department of
Corrections for the sole and exclusive purpose of providing services in a secure
environment to prisoners within a penal institution, penitentiary, prison,
detention center, or other secure correctional institution. This shall include
correctional institutions operated by private entities in this state which house
inmates under the Department of Corrections.
A
hospital, clinic, or other health care facility may apply to the board for an
exemption to be excluded from the definition of this term for purposes of
compliance with this article if compliance would impose an undue hardship on
such facility. The board shall provide guidelines and criteria for what
constitutes an undue hardship which shall include criteria relating to the
amount of indigent patients served and the lack of electronic capability of the
facility.
(5)
'Patient' means the person or animal who is the ultimate user of a drug for whom
a prescription is issued or for whom a drug is dispensed.
(6)
'Prescriber' means a physician, dentist, veterinarian, scientific investigator,
or other person licensed, registered, or otherwise authorized under the laws of
this state to prescribe, distribute, dispense, conduct research with respect to,
or administer a controlled substance in the course of professional practice or
research in this state.
(7)
'Schedule II, III, IV, or V controlled substance' means a controlled substance
that is classified as a Schedule II, III, IV, or V controlled substance under
Code Section 16-13-26, 16-13-27, 16-13-28, or 16-13-29, respectively, or under
the Federal Controlled Substances Act, 21 U.S.C. Section 812.
16-13-123.
(a)
The board and agency may apply for available grants and accept any gifts,
grants, or donations to assist in developing and maintaining the program
established by this article.
(b)
The board shall be authorized to grant funds to dispensers for the purpose of
covering costs for dedicated equipment and software for dispensers to use in
complying with the reporting requirements of this article. Such grants shall be
funded by gifts, grants, donations, or other funds appropriated for the
operation of the prescription monitoring program established under the
provisions of Code Section 16-13-124. The board shall be authorized to
establish standards and specifications for any equipment and software purchased
pursuant to a grant received pursuant to this article. Nothing in this article
shall be construed to require a dispenser to incur costs to purchase equipment
and software to comply with this article.
16-13-124.
(a)
The board shall establish and maintain a program for the monitoring of
prescribing and dispensing of all Schedule II, III, IV, or V controlled
substances.
(b)
Each dispenser shall submit to the board by electronic means information
regarding each prescription dispensed for a Schedule II, III, IV, or V
controlled substance. The information submitted for each prescription shall
include, but not be limited to:
(1)
United States Drug Enforcement Administration (DEA) permit number or approved
dispenser facility identification number;
(2)
Date prescription filled;
(3)
Prescription number;
(4)
Whether prescription is new or a refill;
(5)
National Drug Code (NDC) for drug dispensed;
(6)
Quantity dispensed;
(7)
Number of days' supply of the drug;
(8)
Patient's name;
(9)
Patient's address;
(10)
Patient's date of birth;
(11)
Approved prescriber identification number;
(12)
Date prescription issued by prescriber; and
(13)
Other data elements consistent with standards established by the American
Society for Automation in Pharmacy, if designated by regulations of the
board.
(c)
Each dispenser shall submit the information in accordance with transmission
methods and frequency requirements established by the board but no less often
than weekly and shall report, at a minimum, prescriptions dispensed up to the
day prior to data submission.
(d)
The board may issue a waiver to a dispenser that is unable to submit
prescription information by electronic means acceptable to the board. Such
waiver may permit the dispenser to submit prescription information by paper form
or other means, provided all information required in subsection (b) of this Code
section is submitted in this alternative format subject to the frequency
requirements of subsection (c) of this Code section. Requests for waivers shall
be submitted in writing.
16-13-125.
(a)
Prescription information submitted to the board shall be confidential and shall
not be subject to open records requirements, as contained in Article 4 of
Chapter 18 of Title 50, except as provided in subsections (c) and (d) of this
Code section.
(b)
The board shall establish and maintain strict procedures to ensure that the
privacy and confidentiality of patients and prescribers and patient and
prescriber information collected, recorded, transmitted, and maintained pursuant
to this article are protected. Such information shall not be disclosed to
persons except as otherwise provided in this article and only in a manner which
in no way would conflict with the requirements of the federal Health Insurance
Portability and Accountability Act of 1996, P.L. 104-191. This may include, but
not be limited to, restricting access only to those individuals and entities
which clearly demonstrate a need to know such information.
(c)
The board shall review the prescription information and if there is reasonable
cause to believe a violation of law or breach of professional standards may have
occurred, the board shall notify the appropriate law enforcement or professional
licensing, certification, or regulatory agency or entity and shall provide
prescription information to such agency or entity which may be necessary for an
investigation.
(d)
The board shall be authorized to provide data collected pursuant to this article
to the following persons or under the following circumstances:
(1)
Persons authorized to prescribe or dispense controlled substances for the
purpose of providing medical or pharmaceutical care for their
patients;
(2)
Upon the request of a person about whom the information requested concerns or
upon the request on his or her behalf by his or her attorney;
(3)
The Composite State Board of Medical Examiners or any licensing board whose
practitioners have the authority to prescribe or dispense controlled
substances;
(4)
Local, state, and federal law enforcement, regulatory, or prosecutorial
officials engaged in the administration, investigation, or enforcement of the
laws governing licit drugs and who are involved in a bona fide, specific drug
related investigation involving a designated case;
(5)
Upon the lawful order of a court of competent jurisdiction; and
(6)
Personnel of the agency for purposes of administration and enforcement of this
article, Article 2 of this chapter, the 'Georgia Controlled Substances Act,' or
any other applicable state law.
(e)
The board may provide data to public or private entities for statistical,
research, or educational purposes after removing information that could be used
to identify prescribers or individual patients or persons who received
prescriptions from dispensers.
(f)
The board may provide data to a prescription monitoring program of another state
if the confidentiality, security, and privacy standards of the requesting state
are determined by the board to be equivalent to those of the board.
(g)
Any person who receives data or reports relating to this article from the board
shall not provide such data or reports to any other person except by order of a
court of competent jurisdiction or as otherwise permitted pursuant to this
article.
16-13-126.
The
agency shall be authorized to contract with another state agency or with a
private vendor, as necessary, to ensure the effective operation of the
prescription monitoring program established pursuant to this article. Any
contractor shall be bound to comply with the provisions regarding
confidentiality of prescription information in Code Section 16-13-125 and shall
be subject to the penalties specified in Code Section 16-13-130 for unlawful
acts.
16-13-127.
The
board shall provide notice and information to all prescribers and dispensers in
this state as to the intent of this article, the program established pursuant to
this article, and instructions on how to submit prescription information to the
board via electronic means.
16-13-128.
(a)
There is established a Prescription Monitoring Program Advisory Committee for
the purposes of consulting with and advising the board and the agency on matters
related to the establishment, maintenance, and operation of the prescription
monitoring program established pursuant to this article. This shall include,
but not be limited to, data collection, regulation of access to data, evaluation
of data to identify benefits and outcomes of the program, communication to
prescribers and dispensers as to the intent of the program and how to use the
data base, and security of data collected.
(b)
The advisory committee shall consist of five members, appointed by the board,
which may include individuals representing pharmacies, dentistry, and medical
professionals. The board shall be authorized, but not required, to make such
appointments from recommendations submitted by the Medical Association of
Georgia, the Georgia Dental Association, the Georgia Pharmacy Association, and
the Georgia Society of Health System Pharmacies. Each member of the advisory
committee shall serve a two-year term and until the appointment and
qualification of such member's successor.
(c)
The advisory committee shall elect a chairperson and vice chairperson from among
its membership to serve a term of one year.
(d)
The advisory committee shall meet at the call of the chairperson or upon request
by at least three of the members and shall meet at least one time per year.
Three members of the committee shall constitute a quorum.
(e)
The members shall receive no compensation or reimbursement of expenses from the
state for their services as members of the advisory committee.
16-13-129.
The
board shall promulgate rules and regulations setting forth the procedures and
methods for implementing this article.
16-13-130.
(a)
A dispenser who willfully and intentionally fails to submit prescription
monitoring information to the board as required by this article or willfully and
intentionally submits incorrect prescription information shall be guilty of a
misdemeanor and punished by imprisonment for a period not to exceed 12 months or
a fine not to exceed $1,000.00, or both.
(b)
An individual authorized to have prescription monitoring information pursuant to
this article who willfully and intentionally discloses such information in
violation of this article shall be guilty of a felony and punished by
imprisonment for a period not to exceed ten years or a fine not to exceed
$10,000.00, or both.
(c)
An individual authorized to have prescription monitoring information pursuant to
this article who willfully and intentionally uses such information in a manner
or for a purpose in violation of this article shall be guilty of a felony and
punished by imprisonment for a period not to exceed ten years or a fine not to
exceed $10,000.00, or both.
(d)
The penalties provided by this Code section are intended to be cumulative of
other penalties which may be applicable and are not intended to repeal such
other penalties.
16-13-131.
Nothing
in this article shall require a dispenser or prescriber to obtain information
about a patient from the prescription monitoring program established pursuant to
this article. A dispenser or prescriber shall not have a duty and shall not be
held liable for damages to any person in any civil, criminal, or administrative
action for injury, death, or loss to person or property on the basis that the
dispenser or prescriber did or did not seek or obtain information from the
prescription monitoring program. A dispenser or prescriber acting in good faith
shall be immune from any civil, criminal, or administrative liability that might
otherwise be incurred or imposed for requesting or receiving information from
the prescription monitoring
program."
SECTION
2.
This
Act shall become effective on July 1, 2009.
SECTION
3.
All
laws and parts of laws in conflict with this Act are repealed.
